A new Cleveland Clinic-led study has identified mechanisms by which COVID-19 can lead to Alzheimer's disease-like dementia. The findings, published in Alzheimer's Research & Therapy, indicate an overlap between COVID-19 and brain changes common in Alzheimer's, and may help inform risk management and therapeutic strategies for COVID-19-associated cognitive impairment.
Researchers at the Medical University of South Carolina and Harvard Medical School have identified a previously unknown early driver of Alzheimer's disease (AD) and vascular dementia (VaD). In Science Translational Medicine, they report high levels of cis P-tau, a pathogenic protein, in human AD and VaD brains as well as preclinical disease models. Treatment with an antibody to the toxic protein prevented disease progression and reversed disease symptoms and restored cognitive function in older mice.
Much like a supply truck crossing the countryside, the misfolded proteins that damage neurons in Alzheimer's disease travel the "roads" of the brain, sometimes stopping and sometimes re-routing to avoid roadblocks, reports a study published in Science Advances by researchers at Van Andel Institute and University of Pennsylvania.
Scientists say naked mole rats - a rodent native to West Africa - may hold the key to new treatments for degenerative diseases such as cancer and dementia.
Until now, systemic biomarkers to measure exercise effects on brain function and that link to relevant metabolic responses were lacking. A study shows a memory biomarker, myokine Cathepsin B (CTSB), increased in older adults following a 26-week structured aerobic exercise training. The positive association between CTSB and cognition, and the substantial modulation of lipid metabolites implicated in dementia, support the beneficial effects of exercise training on brain function and brain health in asymptomatic individuals at risk for Alzheimer's.
The team looked in different regions of the brain, which are affected in Alzheimer's disease before looking for common changes across these cortical regions. They identified 220 sites in the genome, including 84 new genes, which showed different levels of DNA methylation in the cortex in individuals with more severe Alzheimer's disease, which weren't seen in the cerebellum.
Research News Tip Sheet: Story Ideas From Johns Hopkins Medicine.
A new study unexpectedly identified tiny deposits of elemental copper and iron within the brains of two deceased people with Alzheimer's disease. The findings could help scientists better understand how these elemental metals, which were uncovered in the cores of amyloid plaques, contribute to neurodegenerative diseases and could point to a target for alternative Alzheimer's therapies.
Millions of adults could lower the chance that they'll ever need a drug to treat dementia including Alzheimer's disease, if they work with their primary care providers and use the power of prevention to keep their brains healthy. A recent review by a national panel of experts summarizes the evidence behind steps providers and patients can take to identify and change modifiable risk factors.
A multidisciplinary team led by researchers from the Spanish Research Council (CSIC) identifies the genomic cellular map associated with hippocampal sclerosis, a major histopathological condition of temporal lobe epilepsy. The study, published in Cell Reports, identifies cell-type specific transcriptional signatures of hyper-excitability and neurodegeneration, providing grounds for improved diagnosis.